BIOTECHNOLOGY EUROPE SECTOR NEWS

Community

Advertising Opportunities

Biotechnology Europe Programs

Resources

Biotechnology Europe Community

Feedback

Contact

Biotechnology Europe Advantages

Advertising Opportunities on Biotechnology Europe

Sponsorship Opportunities on Biotechnology Europe

Post a Job on Biotechnology Europe

Post a Company Profile on Biotechnology Europe

Post a News on Biotechnology Europe

Post an Event on Biotechnology Europe

Post a Product on Biotechnology Europe

Post a Publication on Biotechnology Europe

BIOTECHNOLOGY EUROPE-PRODUCTS NEWS



29.07.2008 European Commission Grants Marketing Authorization for MediGene's Drug Oracea®


25.07.2008 Exclusive Afinion Distribution Agreements signed with Abbot and PSS in USA


21.07.2008 Axis-Shield Afinion patent granted in China


25.06.2008 An Update to Dako's Autostainer Link


09.01.2008 Amarin Announces Successful Outcome of Nasal Lorazepam Study


14.11.2007 Axis-Shield launches fourth AxSYM assay with Abbott


22.10.2007 Anti-Cancer Agent Tarceva^® Tablet, Approved in Japan


21.09.2007 Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union


01.09.2007 Merck Applies to Extend Use of Erbitux® for 1st-Line Colorectal Cancer


31.08.2007 MediGene: European Approval Procedure for the Six-Months Dosage of Cancer Drug Eligard® Successfully Completed


26.06.2007 Pharmion Submits European Marketing Authorization Application for Satraplatin in Combination With Prednisone for the Treatment of Patients With Metastatic Hormone-Refractory Prostate Cancer Who Have Failed Prior Chemotherapy


07.03.2007 Bioject Delivers Multi-Dose Needle-Free Devices for Production Animals to Merial


09.01.2007 Dyax Corp. Issued Two Patents for Use of DX-88 in CTS


04.12.2006 Amgen Responds to Reports About Use and Safety of EPOGEN and Aranesp in CKD Anemia Therapy


04.12.2006 Axis-Shield Plc announces launch of Anti-CCP assay for Abbott's AxSYM Platform


30.11.2006 Anti-Cancer Agent, Herceptin^® Application for Approval of Additional Indication of Operable Breast Cancer with HER2 Overexpression


28.11.2006 Solvay launches, environmentally-friendly biocide for eradication of life-threatening hospital ‘superbugs’


11.11.2006 ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy for up to Nine Years in Patients with Moderate-to-Severe Rheumatoid Arthritis


11.11.2006 Subsequent Course of Rituxan Improved Outcomes in Rheumatoid Arthritis Patients Who Inadequately Responded to TNF Antagonist Therapy

I back I top I